Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.WIL Research Laboratories (WIL), a global contract research organisation (CRO) and a provider of drug development and chemical and food safety services, has appointed David Spaight as CEO and named him to their board of directors.
Subscribe to our email newsletter
Mr Spaight is expected to oversee WIL’s four major businesses – WIL Research Laboratories, Notox, Midwest BioResearch and QS Pharma, and will continue to implement a long-term strategy of integrating the businesses to provide greater value and full service to their clients, across the globe.
Most recently, Mr Spaight served as president of MDS Pharma Services. He managed a team of more than 3,500 professional across 35 sites in 27 countries. During his tenure at MDS, he served on the board of directors for the association of clinical research organizations (ACRO) and was named chairman for 2008.
Previously, Mr Spaight served as senior vice president at Fisher Scientific Products, where he was responsible for the integration of the sales, marketing and research and development teams in North America, Europe and Asia.
Prior to joining Fisher, Mr Spaight spent 20 years with PerkinElmer Life and Analytical Sciences, rising through several management roles to the position of vice president of global sales and marketing.
Mr Spaight said: “Pharma companies around the world are looking for specific expertise in key areas of drug discovery and development. The scientific expertise of our staff is unmatched and provides a strong base for future growth. I look forward to strengthening this organisation as we continue to deliver exceptional value to our clients.”